Abstract
The US Food and Drug Administration (FDA) developed a draft guidance for drug development in amyotrophic lateral sclerosis (ALS) that was issued in February 2018. The FDA draft guidance considered ...
Cite
CITATION STYLE
APA
Andrews, J. A., Bruijn, L. I., & Shefner, J. M. (2019). ALS drug development guidances and trial guidelines. Neurology, 93(2), 66–71. https://doi.org/10.1212/wnl.0000000000007695
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free